IIIHIIII USOO5583242A United States Patent (19) 11 Patent Number: 5,583,242 Schieven (45) Date of Patent: Dec
IIIHIIII USOO5583242A United States Patent (19) 11 Patent Number: 5,583,242 Schieven (45) Date of Patent: Dec. 10, 1996 54 USE OF PHOSPHOTYROSINE L. B. Justement et al., "Regulation of B Cell Antigen PHOSPHATASE INHIBITORS FOR Receptor Signal Transduction and Phosphorylation by CONTROLLING CELLULAR CD45,” Science 252:1839-1842 (1991). PROLFERATION M. R. Gold et al., "Stimulation of Protein Tyrosine Phos phorylation by the B-Lymphocyte Antigen Receptor,' 75 Inventor: Gary L. Schieven, Seattle, Wash. Nature 345.810-813 (1990). M. C. Cam et al., “In Vivo Antidiabetic Actions of Naglivan, 73) Assignee: Bristol-Myers Squibb Company, New An Organic Vanadyl Compound in Streptozotocin-Induced York, N.Y. Diabetes, Diabetes Res. & Clin. Pract. 20:111-121 (1993). A. L. Burkhardt et al., "Anti-Immunoglobulin Stimulation (21) Appl. No.: 450,342 of B Lymphocytes Activates src-Related Protein-Tyrosine Kinases.' Proc. Natl. Acad. Sci. USA 88:7410–7414 (1991). 22 Filed: May 25, 1995 F. M. Uckun et al., “Tyrosine Phosphorylation Is a Manda tory Proximal Step in Radiation-Induced Activation of the Related U.S. Application Data Protein Kinase C Signaling Pathway in Human B-Lympho cyte Precursors,” Proc. Natl. Acad. Sci. USA 90:252-256 62 Division of Ser. No. 189,330, Jan. 31, 1994. (1993). (51 Int. Cl. ........................................ C07F 5/00 C. P. Stewart & A. L. Prote, "Electron Paramagnetic Reso (52 U.S. Cl. ................................... 556/44; 556/1; 556/42; nance Spectra of Some Oxovanadium (IV) Chelates,” J. 556/114: 556/116; 556/17 Chem. Soc. Dalton Trans. 1661-1666 (1972). 58) Field of Search .................................... 556/1, 42, 44, X.-R.
[Show full text]